Navigation Links
Pharmaxis Concludes Special Protocol Assessment with FDA for Bronchitol Phase 3 Trial
Date:6/19/2008

ion for which mucus build up and clearance is a daily problem. Our bronchiectasis program follows closely behind our work in cystic fibrosis where a phase 3 clinical trial is expected to soon close recruitment.''

Pharmaxis is developing Bronchitol as a treatment to improve mucus clearance in the lungs of patients with cystic fibrosis, bronchiectasis and other acute and chronic pulmonary conditions. The U.S. FDA has granted Bronchitol fast track status and it is designated as an orphan drug in the U.S.

Forward-Looking Statements

The statements contained in this media release that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this media release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the potential for Aridol and/or Bronchitol. All forward-looking statements included in this media release are based upon information available to us as of the date hereof, and we assume no obligation to update any such forward-looking statement as a result of new information, future events or otherwise. We cannot guarantee that any product candidate will receive FDA or other regulatory approval or that we will seek any such approval. Factors that could cause or contribute to such differences include, but are not limited to, factors discussed in the "Risk Factors and Other Uncertainties" section of our Form 20-F lodged with the U.S. Securities and Exchange Commission.

CONTACT:

Alan Robertson

Chief Executive Officer

Tel: +61-2-9454-7200

Email: alan.robertson@pharmaxis.com.au

Released through:

United States:

Brandon Lewis, Trout Group

Tel: +1-646-378-2915

Email: blewis@troutgro
'/>"/>

SOURCE Pharmaxis Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Pharmaxis Establishes Named Patient Program for Bronchitol
2. Pharmaxis Long-Term Safety Study of Bronchitol Completes
3. Alseres Pharmaceuticals Concludes Enrollment in the Cethrin(R) Phase I/IIa Clinical Trial in Acute Spinal Cord Injury
4. FDA Concludes There is No Increased Risk of Cardiac Events for Patients Treated with omeprazole and NEXIUM(R) (esomeprazole magnesium)
5. Karmanos Doctors Urge Increased Screening for Previously Treated Lung Cancer Patients, Especially Young Women
6. Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations
7. Diplomat Specialty Pharmacy Develops and Launches Best-In-Class Electronic Navigator (eNAV(TM)) Patient Care System
8. Texas Heart(R) Institute at St. Lukes Episcopal Hospital Initiates First Clinical Trial in the World to Treat a Heart Attack Patient with a Special Stem Cell Type
9. Most Back Pain Could Be Cured Without Surgery or Drugs if Doctors Treated Muscles - Not the Spine - Says Leading Pain Specialist
10. Specialized Genasense(R) Clinical Trials Featured at AACR Meeting
11. Associated Foot & Ankle Specialists Enrolling Patients With Chronic Diabetic Foot Ulcers for MATRIX Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... 2015 A power morcellator lawsuit ( http://www.morcellatorlawsuit2015.com ... for an undisclosed amount, Bernstein Liebhard LLP reports. According ... 2014 in the U.S. District Court, Eastern District of ... widower whose wife had died in February 2013, just ... involved the use of a power morcellator. Following the ...
(Date:7/7/2015)... Juli 2015 Sequent Medical, ein ... Entwicklung innovativer Geräte für die Behandlung neurovaskulärer ... von R. Michael Kleine in den ... verfügt über eine mehr als 25-jährige Erfahrung ... hat verschiedene globale biomedizinische Unternehmen erfolgreich geleitet ...
(Date:7/7/2015)... -- According to a new market research report ... Instrument), Application (Aerobic, Anaerobic, Yeast/ Fungi) & End User (Hospital, ... 2019", published by MarketsandMarkets, The global Blood Culture Tests Market ... Million in 2014 at a CAGR of 7.2% from 2014-2019. ... ma rket data T ables and ...
Breaking Medicine Technology:Lina Medical, Power Morcellator Lawsuit Plaintiff Reach Settlement in Case Scheduled for November Trial, Bernstein Liebhard LLP Reports 2Lina Medical, Power Morcellator Lawsuit Plaintiff Reach Settlement in Case Scheduled for November Trial, Bernstein Liebhard LLP Reports 3Sequent Medical beruft Mike Kleine in den Aufsichtsrat 2Sequent Medical beruft Mike Kleine in den Aufsichtsrat 3Blood Culture Tests Market Worth $3,893.5 Million by 2019 2Blood Culture Tests Market Worth $3,893.5 Million by 2019 3Blood Culture Tests Market Worth $3,893.5 Million by 2019 4
... Boston Scientific Corporation (NYSE: BSX ) ... MADIT-CRT trial data in the current issue of the ... showed women received a greater clinical benefit from cardiac ... sub-analysis demonstrated that both men and women experienced significant ...
... CUPERTINO, Calif., Feb. 8, 2011 DURECT Corporation (Nasdaq: ... CreoSalus, Inc., has launched commercial sales of its Food ... Equine, an injectable animal health drug utilizing DURECT,s SABER™ ... a royalty on net sales of SucroMate and will ...
Cached Medicine Technology:Boston Scientific Welcomes Publication of Gender Data Highlighting Benefits Women Receive From CRT-Ds 2Boston Scientific Welcomes Publication of Gender Data Highlighting Benefits Women Receive From CRT-Ds 3Boston Scientific Welcomes Publication of Gender Data Highlighting Benefits Women Receive From CRT-Ds 4DURECT Announces Launch of First FDA Approved SABER™-Injectable Peptide Product 2DURECT Announces Launch of First FDA Approved SABER™-Injectable Peptide Product 3
(Date:7/7/2015)... and CHICAGO (PRWEB) , ... July 07, 2015 ... ... healthcare business development and growth strategy expert Jay Warden as Senior Vice President, ... for the company’s efforts to provide the best solutions to healthcare providers’ needs ...
(Date:7/7/2015)... ... July 07, 2015 , ... More than ... Dial and Howdy’s, raised more than $524,286 during the Muscular Dystrophy Association's ... $100,000, to help support children fighting muscular dystrophy and related life-threatening diseases ...
(Date:7/7/2015)... York, NY (PRWEB) , ... July 07, 2015 , ... ... thing that can help pass those long, stressful days at work is knowing that ... aren’t always as laid back and stress free as imagined. Planning for a vacation ...
(Date:7/7/2015)... ... July 07, 2015 , ... This week Northeast Nebraska Imaging, ... website. The website’s goal is to provide patients with detailed information about the ... requesting appointments online. , Part of the center’s rebranding efforts, the website was ...
(Date:7/7/2015)... ... July 07, 2015 , ... Seattle-based ... have merged to form Camber Collective. Camber Collective provides strategic advisory services ... SwitchPoint’s strategy consulting expertise with Hope Consulting’s deep experience in customer insights, ...
Breaking Medicine News(10 mins):Health News:Hammes Company Hires Jay Warden to Lead Healthcare Advisory Services 2Health News:Hammes Company Hires Jay Warden to Lead Healthcare Advisory Services 3Health News:Western Refining Raises $524,286 to Help Send Kids with Neuromuscular Disease to MDA Summer Camp 2Health News:Western Refining Raises $524,286 to Help Send Kids with Neuromuscular Disease to MDA Summer Camp 3Health News:Difass USA Offers Eight Tips to Help Relax and Enjoy Summer Vacation 2Health News:Difass USA Offers Eight Tips to Help Relax and Enjoy Summer Vacation 3Health News:Northeast Nebraska Imaging Launches New Patient Friendly Website 2Health News:SwitchPoint and Hope Consulting Have Merged to Form Camber Collective 2
... N.C., Jan. 29 In today,s volatile ... unwary,pharmaceutical company and nullify product forecasts, sales ... on competitors,products and operations, a high-functioning Competitive ... opportunities as well as warn,them about potential ...
... Collaboration with Harvard Medical International Provides ... Vital Global Health Information, BALTIMORE, Jan. 29 ... reach of their groundbreaking MEDEX,360m partnership with the launch ... and leisure travelers., Like the original MEDEX 360m ...
... that it takes 50,000 lying side by side to equal ... to be highly accurate vehicles for administering medicines and other ... what happens to the tubes after they discharge their medical ... Now, Stanford researchers, who spent months tracking the tiny tubes ...
... an in utero stem cell treatment could lead to ... as a range of other disabling,conditions, according to a ... (UQ). , Action Medical Research has announced the outcomes ... led by Professor Nicholas Fisk, that could lead to ...
... of DNA in the human genome that originated from ... bodies and are even essential for a healthy pregnancy, ... Microbiology Today. , Retrovirus infections represent the most intimate ... genome into the DNA of the host cell, resulting ...
... security, reduces risk and ... supports ... global,provider of integrated security, risk and audit management solutions, today,announced ... Service (NHS) has selected its flagship SecureVue(R) platform to,proactively manage ...
Cached Medicine News:Health News:Building and Sustaining Impactful Competitive Intelligence Organizations for Pharma 2Health News:MEDEX / Harvard Partnership Now Offers Affordable, New Intelligence to Individual Business & Leisure Travelers 2Health News:New nanotube findings by Stanford researchers give boost to potential biomedical applications 2Health News:New nanotube findings by Stanford researchers give boost to potential biomedical applications 3Health News:Stem cell treatment for brittle bones in the womb 2Health News:The North Western Deanery of UK's National Health Service Selects eIQnetworks' SecureVue for Comprehensive IT Assurance 2Health News:The North Western Deanery of UK's National Health Service Selects eIQnetworks' SecureVue for Comprehensive IT Assurance 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: